IBRX Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: ImmunityBio, Inc.

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

3 days ago - By: Zacks Investment Research - Mentions: MYGN

Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3

15 days ago - By: Benzinga - Mentions: OPEN PLUG AI GME ...

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

2 months ago - By: Stocktwits

ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals

2 months ago - By: Stocktwits - Mentions: HIMS RKT SOUN OPEN ...

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts

3 months ago - By: The Motley Fool

IBRX Sales Soar 2,540%

2 months ago - By: ImmunityBio, Inc.

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

2 months ago - By: Yahoo Finance

ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform

2 months ago - By: Benzinga

What's Going On With ImmunityBio Shares Tuesday?

2 months ago - By: ImmunityBio, Inc.

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

3 months ago - By: ImmunityBio, Inc.

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

3 months ago - By: Yahoo Finance

ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates

3 months ago - By: Yahoo Finance

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

3 months ago - By: ImmunityBio, Inc.

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

3 months ago - By: ImmunityBio, Inc.

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

3 months ago - By: Zacks Investment Research - Mentions: LFCR

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

3 months ago - By: ImmunityBio, Inc.

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

3 months ago - By: Yahoo Finance

Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations

3 months ago - By: Yahoo Finance

ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer

3 months ago - By: ImmunityBio, Inc.

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

3 months ago - By: ImmunityBio, Inc.

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

4 months ago - By: Yahoo Finance

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency

4 months ago - By: ImmunityBio, Inc.

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

4 months ago - By: Yahoo Finance

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA

5 months ago - By: ImmunityBio, Inc.

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

5 months ago - By: ImmunityBio, Inc.

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

5 months ago - By: ImmunityBio, Inc.

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

6 months ago - By: Zacks Investment Research - Mentions: JNJ MRK CGON

IMMUNITYBIO INC (IBRX) Stock News

IBRX Latest News, Press Relases and Analysis

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals

Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts

IBRX Sales Soar 2,540%

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform

What's Going On With ImmunityBio Shares Tuesday?

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates

ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

ImmunityBio (IBRX) Reports Q2 Loss, Tops Revenue Estimates

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations

ImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder Cancer

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

ImmunityBio’s (IBRX) ANKTIVA Gets Approved by UK’s Medicines and Healthcare Regulatory Agency

UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVA

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success